Over the years, the field of asthma management has witnessed significant advancements. This article provides an up-to-date review of these developments, highlighting their implications for healthcare professionals.
Biologics have emerged as a promising addition to the asthma management arsenal. They target specific immune pathways, offering a more personalized treatment approach. Biologics like Omalizumab, Mepolizumab, and Benralizumab have shown efficacy in managing severe asthma and reducing exacerbations. However, their high cost and need for subcutaneous administration present challenges.
Digital health technologies have made their way into asthma management with the advent of smart inhalers. These devices record and transmit data about medication usage, helping to monitor adherence and optimize treatment. Preliminary studies suggest that smart inhalers could improve asthma control and reduce hospital visits.
Fractional exhaled nitric oxide (FeNO) testing is a non-invasive method to assess airway inflammation, a key component of asthma. FeNO levels can guide treatment decisions and monitor response to therapy. Despite its potential, FeNO testing is not yet widely adopted in clinical practice, partly due to concerns about its specificity and cost-effectiveness.
The COVID-19 pandemic has accelerated the use of telemedicine in asthma management. Virtual consultations can provide continuous care while minimizing exposure risk. Telemedicine also facilitates home monitoring and timely intervention, although it requires robust digital infrastructure and patient engagement.
The recent advances in asthma management, including biologics, smart inhalers, FeNO testing, and telemedicine, offer exciting possibilities for personalized care and improved patient outcomes. However, they also bring new challenges that healthcare professionals must navigate. Continued research and education are crucial to fully harness these innovations for the benefit of asthma patients.
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Cancer mortality continuing to decline, says report
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
1.
Different Types of Blood Dyscrasias
2.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
3.
Lymphomatoid Papulosis: What You Need to Know
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Oncology
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation